Suzhou Ribo Life Science swings to FY26 H1 profit of RMB 23.45 million; revenue rises to RMB 419.74 million

• Suzhou Ribo Life Science posted revenue of RMB 419.7 million, up 304.3% year over year.
• Profit attributable to owners swung to RMB 20.3 million; basic and diluted EPS turned positive at RMB 0.12.
• R&D expenses climbed 53% to RMB 197.6 million; administrative expenses rose 20.9% to RMB 63 million.
• Growth was driven by licensing revenue under the Madrigal collaboration, supported by Boehringer Ingelheim MASH milestones.
• Cash and cash equivalents rose to RMB 2.24 billion; July updates included Madrigal’s first candidate nomination milestone and 569,400 H-share repurchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12302733), on August 27, 2026, and is solely responsible for the information contained therein.